Investment

Primetime Partners get ready for Longevity primetime

New VC firm seeks start-ups who are working to solve the “urgent problems” facing today’s aging society. This summer, a new venture capital firm was...

Grifols to acquire Longevity innovator Alkahest for $146 million

Blood-based therapy developer to be 100% acquired by existing investor. Longevity-focused biopharma firm Alkahest, which is developing therapies derived from blood, is to be acquired...

Biofourmis raises $100M to scale digital therapeutics

Health start-up Biofourmis, which leverages AI for personalised healthcare monitoring, has raised $100m from SoftBank. SoftBank Group has led a $100m investment in Biofourmis, the...

Deep Longevity acquired by Regent Pacific

Hong Kong public company enters Longevity business by acquiring aging clock specialist Deep Longevity. Not even two months after it exited stealth to announce its...

ARDD 2020: Addressing the challenges in drug discovery

We speak to the co-founder of Molecule about building a unique marketplace for early stage therapeutic development. Next week (September 1 - 4), the annual...

The billionaires are coming!

Longevity Investors Conference aims to focus the investment spotlight on developments in anti-aging science. As Greg Bailey told us last week: "When I was talking...

AgeTech investment: “there is everything to play for”

AgeTech Accelerator's Lorraine Morley on market disconnect, helping investors take the plunge and shaping the AgeTech market. Continuing our series of interviews with our Advisory Panel...

Targeting multiple Longevity biomarkers in a single panel

Jinfiniti raising $5m as it prepares to launch new biomarkers test panel that measures genomic instability, epigenetic alteration, inflammation, cellular senescence, oxidative stress, tissue...

Juvenescence (2): “It’s all about prevention, and that’s incredibly disruptive”

Juvenescence's Greg Bailey on democratising healthcare, paradigm shifts and disruptive technologies. Yesterday we published the first part of our interview with Greg Bailey, CEO of...

Juvenescence (1): from strength to strength in R&D and investment firepower

Juvenescence's Greg Bailey on transformative scientific opportunities, immuno-resilience, modifying aging and funding. Continuing our series of interviews with our Advisory Panel members, we spoke to Greg...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

First Longevity announces first investors for current round

Some news of our own: European VC fund and a Longevity innovator participate in the First Longevity funding round. Last week we announced that Tom...

Longevity opportunities in the post-Covid world

Longevity International’s Tina Woods discusses how Covid-19 has catapulted health to the top of the global agenda. Tina Woods is CEO and co-founder of Longevity...

All the way from regenerative research to commercialisation

We speak to the director of the Wake Forest Institute of Regenerative Medicine – a research organisation with a clear focus on commercialisation. Just on...

$85m funding for epigenetic platform technology

Omega Therapeutics secures $85m to carry out clinical trials into epigenetic treatments for five key disease areas – and potentially for Covid-19.  While you might...

Tonus seeks early-stage funding for exoskeleton tech

Company spawned by London start-up generator targets middle-aged recreational athletes with exoskeleton leggings powered by soft robotics. Back in November, we brought you the story...

Aubrey de Grey: “Damage repair is the future of Longevity medicine”

SENS Research Foundation's Aubrey de Grey on increasing investor appetites and the elephant in the Longevity room. Continuing our series of interviews with our Advisory Panel...

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

de Magalhães interview: “Still lots of work to do”

Professor João Pedro de Magalhães on different areas of Longevity. Continuing our series of interviews with our Advisory Panel members, we caught up with João Pedro...

SyndicateRoom co-founder joins First Longevity

Tom Britton joins Advisory Panel as plans for Longevity equity funding platform take another step forward. Longevity.Technology: Just last month we announced the formation of...

Latest articles

Combining existing medicines to target aging

Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug. Already well-known for its beer and bureaucracy to its...

Stem cells could identify new treatments for Parkinson’s

Scientists believe they may have made a significant leap forward in the fight against Parkinson’s disease with the discovery of cells which could help...

Longevity marketing and the need for clarity

Dr Oliver Zolman makes the case for Longevity companies adopting a checklist when it comes to making anti-aging claims. When it comes to marketing in...

The interferons are coming to senolytic aging therapies

A new report suggests that studying the relationship between interferons and senescence could be key to developing new anti-aging therapies.  There are some things which...